Join the launch event for HPP’s work on UK readiness for radioligand therapy
17 August 2021
As part of the radioligand therapy project, The Health Policy Partnership (HPP) will hold an online event on 9 September to launch the UK application of the Radioligand Therapy Readiness Assessment Framework.
The event, ‘Achieving readiness for radioligand therapy in the UK’, will feature leading clinicians and experts from Prostate Cancer UK, Neuroendocrine Cancer UK and the British Nuclear Medicine Society discussing how to improve current integration and future readiness for radioligand therapy. The event will outline how to implement multi-sectoral working to drive proactive policymaking for radioligand therapy, and explore how the UK can achieve a ready system that can successfully integrate new targeted cancer therapies.
HPP has developed a policy action blueprint for radioligand therapy and accompanying situation analysis report. The report analyses the current integration of radioligand therapy in the UK and the blueprint offers policy recommendations for achieving health system readiness for the therapy.
The launch will take place from 14:00 to 15:30 BST on Thursday, 9 September and will be moderated by Dr Suzanne Wait, Managing Director of The Health Policy Partnership.
- Dr Martin Rolles, Radiotherapy Lead, Wales Cancer Network
- Dr John Buscombe, Former President, British Nuclear Medicine Society; Locum Consultant, Barts Health NHS Trust
- Ms Nikie Jervis, Patient Support Manager and Information Nurse Specialist, Neuroendocrine Cancer UK
- Ms Karen Stalbow, Head of Policy, Knowledge and Impact, Prostate Cancer UK
Plus more to be announced.
This event took place on the 9 September 2021. Read the recap and download the policy action blueprint and situation analysis report here.
Radioligand therapy is a highly targeted cancer therapy which has the potential to improve and extend the lives of people with certain types of cancer. Find out more on the radioligand therapy website.